X-ZELL Company
![](/files/companies/X-ZELL.png)
X-ZELL’s vision is to save lives by identifying clinically significant cancers early, when there is still time to act and take charge of our health. X-ZELL first made headlines in 2017 when it found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Known to be powerful biomarkers for the early detection of aggressive cancers, tCEC were long considered ‘undetectable’ in clinical routine. X-ZELL overcame the impasse by developing a platform technology that is capable of detecting a single tCEC among five billion healthy blood cells and analysing it using Artificial Intelligence – making for an affordable, non-invasive solution with maximum scalability. Less than a year after that breakthrough, X-ZELL was able to present the world’s first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. But one cancer is not enough. X-ZELL’s ambition is to make accurate, affordable tCEC screening available to everyone, everywhere – which is why additional tests for common cancers such as breast, ovarian, colon and lung have already gone into pre-development, with more to come. They all feed into the creation of an AI-driven general screening test that will be able to scrutinise our blood for atypical cells and analyse them on-screen – allowing physicians to manage our health proactively instead of just responding to a disease.